eli lilly glp-1 drug launches pill, kicking off showdown with Novo Nordisk Novo Nordisk injectable underperforms vs.

Instead, the FDA cited 'deficiencies in the manufacturing and chemistry documentation (CMC).' This means the issues are related to the paperwork and processes around how the drug is made, rather than how well it works or its side effects in patients

In addition to NAFLD, NASH is also of concern, with limited treatment options

Palmer, B

The most frequent adverse events with survodutide versus placebo were nausea (66% versus 23%), diarrhea (49% versus 23%), and vomiting (41% versus 4%) 30

doi: 10.1007/s00592-011-0359-9

The microdose protocol is particularly suited for patients with prior GI sensitivity, those new to injectable medications, or individuals with genetic variations that may increase medication sensitivity